+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Current treatment of locally advanced and metastatic prostate cancer



Current treatment of locally advanced and metastatic prostate cancer



Wiener Medizinische Wochenschrift 161(15-16): 377-381



Despite the broad use of PSA-testing in western medicine, still an estimated 1/3 of carcinomas of the prostate (PC) are diagnosed in a locally advanced or metastatic stage. In the current treatment-algorithm for locally advanced PC, radical prostatectomy, external beam radiation therapy (with and without hormonal therapy) and primary androgen deprivation are available. In fact, in a majority of patients treatment of this tumor stage will be a multimodal approach, which has to be discussed individually. For metastatic PC hormonal deprivation therapy is still the gold standard. Beside LHRH-agonists, surgical castration and complete androgen deprivation today LHRH-antagonists represent the different therapeutic options in this tumor stage. Effects on natural course of this disease have to be balanced to the side effects of long-term therapy. Castration-resistant PC is not the object of this overview even though there are a variety of new medical interventions emerging for the treatment of this stage of PC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052414617

Download citation: RISBibTeXText

PMID: 21953428

DOI: 10.1007/s10354-011-0014-7


Related references

Castration in the treatment of locally advanced or metastatic prostate cancer. La Revue du Praticien 63(4): 509-510, 2013

Evolving treatment paradigms for locally advanced and metastatic prostate cancer. Expert Review of Anticancer Therapy 6(11): 1639-1651, 2006

Radiation therapy for the treatment of locally advanced and metastatic prostate cancer. Hematology/Oncology Clinics of North America 15(3): 423-443, 2001

Innovations in hormonal treatment for locally advanced and/or metastatic prostate cancer. Progres en Urologie 21 Suppl 3: S96-101, 2011

Medical castration in the treatment of locally advanced or metastatic prostate cancer: an update. Progres en Urologie 19 Suppl 1: S15-S19, 2009

Evaluating the Safety of Up-front Docetaxel in the Treatment of Metastatic and Locally Advanced Prostate Cancer. Clinical Oncology 31(2): e22-e23, 2019

Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. European Journal Of Cancer. 29a(8): 1088-1093, 1993

Locally advanced and metastatic gastric cancer: current management and new treatment developments. Drugs 68(3): 299-317, 2008

Current treatment in high risk and locally advanced prostate cancer. Actas Urologicas Espanolas 31(5): 445-451, 2007

Medical management in locally advanced and metastatic prostate cancer: Does changes in treatment policy have any specific effect on PSA levels?. Archivio Italiano di Urologia, Andrologia 89(4): 282-286, 2018

Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Oncotargets and Therapy 7: 751-759, 2014

Zoladex with or without flutamide in the treatment of locally advanced or metastatic prostate cancer interim analysis of an ongoing poncap study. European Urology 18(SUPPL 3): 48-53, 1990

A randomised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. European Urology 33(5): 447-456, 1998

Unmet Supportive Care Needs of Men With Locally Advanced and Metastatic Prostate Cancer on Hormonal Treatment: A Mixed Methods Study. Cancer Nursing 40(6): 497-507, 2017

Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer. Clinical Oncology ) 28(6): 376-385, 2017